ประเภททั้งหมด
| Product Name | คําอธิบาย | Action |
|---|---|---|
| Cetuximab,Erbitux,EGFR,IMC-C225,Anti-EGFR monoklonal antibody,Chimeric IgG1 antibody,Oncology biologic / Colorectal cancer antibody / Head and neck cancer antibody, CAS No.205923-56-4 การรักษาความปลอดภัยของร่างกาย | Trade Name : Erbitux Target : EGFR Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 650(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Aflibercept | Trade Name : Eylea Target : VEGF/PlGF Molecular Type : Fusion Protein Sales in 2025 (Millions of USD) : 7770(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Trastuzumab Emtansine,Kadcyla,Her2,T-DM1,Ado-trastuzumab emtansine,HER2-targeted ADC,Microtubule inhibitor conjugate,Non-cleavable linker ADC,Maytansinoid ADC, ADC รุ่นที่สอง | Trade Name : Kadcyla Target : Her2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 2000~2200(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Trastuzumab Deruxtecan,Enhertu,Her2,DS-8201a,Fam-trastuzumab deruxtecan-nxki,ADC รุ่นที่สาม,ADC ที่เป้าหมาย HER2,สารสับสน inhibitor Topoisomerase I, CAS No. 1826843-81-5 | Trade Name : Enhertu Target : Her2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 4500~5000(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| ทราสทูซูแมบ | Trade Name : Herceptin Target : Her2 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 3000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Nivolumab และ berahyaluronidase alfa-pmph, Opdivo SC, Opdivo การฉีดภายใต้ผิวหนัง, Opdivo Qvantig, BMS-986251, หมัก PD-1 ภายใต้ผิวหนัง, ผลิตภัณฑ์รวม (901 และ 932) | Trade Name : Opdivo Qvantig® Target : N/A Molecular Type : Combination Product (901 and 932) Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Nivolumab และ rmbw ที่เกี่ยวข้อง Opdualag การฉีด,PD-1, LAG-3,BMS-986213,PD-1 / LAG-3 หน่วงยับคู่ | Trade Name : Opdualag Target : PD-1, LAG-3 Molecular Type : Fixed-dose Combination (902 and 962) Sales in 2025 (Millions of USD) : 1000~1200(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get ... |
|
| Nivolumab, Opdivo, PD-1, BMS-936558, ONO-4538, Anti-PD-1, หน่วงจุดตรวจภูมิคุ้มกัน, แอนติบอดีโมโนคลอน, CAS No 946414-94-4 | Trade Name : Opdivo Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 12000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
